Clinical Trial

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 29, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT119X(including CT1190-P and CT1192) CAR-T Cell therapy, in Patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia.
Trial Details
NCT Number NCT07043218
Lead Sponsor Shanghai Tongji Hospital, Tongji University School of Medicine
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 36 participants
Start Date 2025-07-10
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-29